When Raynaud's Becomes Severe: Ulcers and Ischemia
At a Glance
Severe Raynaud's can reduce blood flow enough to cause persistent pain, digital ulcers, tissue death, or infection. A cold or pale digit that does not improve with warming, tissue discoloration, or infection signs needs urgent medical evaluation; emergency symptoms require immediate care.
While most cases of Raynaud’s are manageable with lifestyle changes and oral medications, some individuals—particularly those with secondary Raynaud’s related to conditions like systemic sclerosis—may develop severe complications [1]. These complications occur when blood flow is so severely restricted that the skin and underlying tissues begin to break down [2]. Recognizing the signs of “critical” disease is essential for protecting your hands and feet from permanent damage.
Urgent Signs: The Red Flags
In a typical Raynaud’s attack, your skin color returns to normal once you warm up. However, certain symptoms indicate that the blood supply is not returning as it should. These require medical evaluation rather than just waiting for your next office appointment [3][4].
Urgent (Call your doctor for a prompt, often same-day assessment):
- Digital Ulcer: A new or non-healing small ‘pit’, open sore, or wound on the fingertip or near the nail [5].
- Persistent Rest Pain: Intense, throbbing pain in a digit that continues even when you are fully warm [6].
Emergency (Go to the nearest emergency department immediately):
- Sudden Severe Ischemia: Rapid loss of sensation, severe weakness, a persistently cold/pale digit that doesn’t improve, or an absent pulse.
- Tissue Death (Necrosis/Gangrene): Skin that turns permanently black, dark gray, or necrotic. (Do not self-diagnose gangrene based merely on a temporary blue color during a normal attack) [6].
- Severe Infection: Rapidly spreading redness, increased swelling, pus, red streaks moving up the hand, or fever and chills associated with a sore [7].
Hospital-Based Treatment: IV Prostanoids
When oral medications are not enough to restore blood flow or heal a severe ulcer, specialists may recommend intravenous (IV) prostanoids, such as iloprost or epoprostenol [8][9].
- How they work: These powerful medications are “super-vasodilators.” They forcefully open blood vessels and help prevent blood cells from clumping together (anti-platelet effect) [5].
- The Procedure: These are specialist treatments reserved for selected severe ischemia or ulcers. Because these drugs can significantly lower your blood pressure, they are typically given in a hospital or specialized clinic where you can be monitored [10]. Availability, licensing, and infusion protocols (such as a 3–5 day cycle) vary by country, and your doctor must also assess you for vascular obstruction and infection [11].
- Side Effects: Many patients experience a “flushing” sensation, headache, nausea, or jaw pain during the infusion [12]. These usually fade quickly once the infusion is slowed or stopped.
Preventing New Damage: Bosentan
For patients with systemic sclerosis who have a history of recurring sores, a medication called bosentan may be prescribed as a specialist option [10].
- Prevention, Not Cure: Bosentan is an endothelin receptor antagonist. It blocks a chemical in your body that causes blood vessels to tighten. Research shows it is effective at reducing the number of new ulcers that form, but it generally does not help heal existing ulcers or treat standard Raynaud’s attacks [13][14].
- Crucial Safety Monitoring: Bosentan carries significant risks. It is highly teratogenic (can cause severe birth defects), so treatment requires strict pregnancy testing and reliable contraception. It can also reduce the effectiveness of hormonal contraceptives. Because it affects the liver, patients must have regular blood tests (often monthly, according to the product label) to check liver enzymes and hemoglobin levels [15][16].
Surgical and Advanced Options
If medications fail and tissue is at risk, surgical intervention may be considered as a last-resort specialist option.
- Digital Sympathectomy: This is a specialized surgery where a surgeon carefully strips away the tiny nerves surrounding the arteries in your hand to prevent them from sending the “spasm” signals to the blood vessels [17][8].
- Success Rates: While some observational series report high rates of immediate pain relief, this is not a dependable expectation for all patients [18].
- Recurrence: It is important to know that the effects have uncertain durability. Symptoms often return months or years later as the body adapts [18][19].
- Botulinum Toxin (Botox) Injections: Some doctors use Botox injections into the palm or fingers to block the release of neurotransmitters that cause vasospasm [20]. While some small studies show it helps heal ulcers and reduce pain, a large clinical trial found it was not significantly better than a placebo for overall Raynaud’s symptoms [21][20]. It remains an “off-label” or investigational option with mixed evidence.
- Wound Care and Debridement: If an area of skin has become necrotic (died), specialized vascular and wound care is required [7]. However, ischemic dry necrosis or a stable scab is not automatically surgically debrided (removed) before perfusion and infection status are assessed; premature debridement can enlarge a wound. Decisions are highly case-dependent. In the most severe, untreated cases where blood flow cannot be restored, a partial amputation may be necessary to protect the rest of the hand [17]. Early intervention with the “red flag” symptoms above is the best way to avoid these outcomes.
Common questions in this guide
How do I know whether a Raynaud's episode is an emergency?
What does a digital ulcer from Raynaud's look like?
When are IV prostanoids used for severe Raynaud's?
Can bosentan heal an existing Raynaud's ulcer?
Can digital sympathectomy permanently stop severe Raynaud's symptoms?
Should dead-looking skin from Raynaud's always be removed?
How do doctors check for an infection or a blocked artery?
Get notified when new evidence is published on Raynaud disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (21)
- 1
Raynaud's phenomenon-an update on diagnosis, classification and management.
Pauling JD, Hughes M, Pope JE
Clinical rheumatology 2019; (38(12)):3317-3330 doi:10.1007/s10067-019-04745-5.
PMID: 31420815 - 2
Primary and Secondary Raynaud: A Scientific Statement From the American Heart Association.
Ujueta F, Goudot G, Cutolo M, et al.
Circulation 2026; (154(13)):e505-e517 doi:10.1161/CIR.0000000000001464.
PMID: 42639644 - 3
Raynaud's phenomenon.
Haque A, Hughes M
Clinical medicine (London, England) 2020; (20(6)):580-587 doi:10.7861/clinmed.2020-0754.
PMID: 33199324 - 4
Differential diagnosis of critical digital ischemia in systemic sclerosis: Report of five cases and review of the literature.
Sharp CA, Akram Q, Hughes M, et al.
Seminars in arthritis and rheumatism 2016; (46(2)):209-216 doi:10.1016/j.semarthrit.2016.05.001.
PMID: 27318627 - 5
A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
Shenavandeh S, Sepaskhah M, Dehghani S, Nazarinia M
Clinical rheumatology 2022; (41(1)):95-104 doi:10.1007/s10067-021-05900-7.
PMID: 34471968 - 6
Successful treatment of jellyfish sting-induced severe digital ischemia with intravenous iloprost infusion.
Lo AH, Chan YC, Law Y, Cheng SW
Journal of vascular surgery cases 2016; (2(1)):31-33 doi:10.1016/j.jvsc.2016.02.007.
PMID: 31724607 - 7
Peripheral Nerve Blockade for Patients With Raynaud Phenomenon and Other Causes of Digital Ischemia: A Case Report and Practice Implications.
Stephas SA, Hertel P, Bennetts P
AANA journal 2021; (89(5)):391-395.
PMID: 34586992 - 8
Pharmacotherapy Options in the Management of Raynaud's Phenomenon.
Hinze AM, Wigley FM
Current treatment options in rheumatology 2018; (4(3)):235-254 doi:10.1007/s40674-018-0102-6.
PMID: 31538045 - 9
Evidence for the Use of Epoprostenol to Treat Raynaud's Phenomenon With or Without Digital Ulcers.
Cruz JE, Ward A, Anthony S, et al.
The Annals of pharmacotherapy 2016; (50(12)):1060-1067 doi:10.1177/1060028016660324.
PMID: 27465880 - 10
Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee.
Maltez N, Ross L, Baron M, et al.
Journal of scleroderma and related disorders 2025; (10(3)):267-275 doi:10.1177/23971983251340559.
PMID: 40852405 - 11
Treatment of digital ulcers in systemic sclerosis: Case series study of thirteen patients and discussion on outcome.
Abuowda Y, Almeida RS, Oliveira AA, et al.
Revista da Associacao Medica Brasileira (1992) 2017; (63(5)):422-426 doi:10.1590/1806-9282.63.05.422.
PMID: 28724039 - 12
Lumbar sympathectomy versus prostanoids for critical limb ischaemia due to non-reconstructable peripheral arterial disease.
Sen I, Agarwal S, Tharyan P, Forster R
The Cochrane database of systematic reviews 2018; (4()):CD009366 doi:10.1002/14651858.CD009366.pub2.
PMID: 29658630 - 13
Effectiveness of bosentan in the treatment of systemic sclerosis-related digital ulcers: Systematic review and meta-analysis.
Hosseinbalam M, Nouri R, Farajzadegan Z, Mottaghi P
Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2023; (28()):3 doi:10.4103/jrms.jrms_386_22.
PMID: 36974107 - 14
Bosentan versus nifedipine in the treatment of vasculopathy in systemic sclerosis patients: A randomized control trial.
Phat TN, Luong VH, Minh VN, et al.
Asian Pacific journal of allergy and immunology 2025; (43(3)):706-711 doi:10.12932/AP-070722-1406.
PMID: 36278776 - 15
Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
Wei A, Gu Z, Li J, et al.
Journal of the American Heart Association 2016; (5(11)).
PMID: 27912207 - 16
Safety and tolerability of bosentan for digital ulcers in Japanese patients with systemic sclerosis: Prospective, multicenter, open-label study.
Hamaguchi Y, Sumida T, Kawaguchi Y, et al.
The Journal of dermatology 2017; (44(1)):13-17 doi:10.1111/1346-8138.13497.
PMID: 27374274 - 17
Distal periarterial sympathectomy surgery for chronic digital ischemia: A systematic review of the literature.
Cereceda-Monteoliva N, Smart YW, Ojelade E, et al.
Journal of orthopaedics 2024; (50()):76-83 doi:10.1016/j.jor.2023.11.072.
PMID: 38179435 - 18
Surgical treatment of systemic sclerosis--is it justified to offer peripheral sympathectomy earlier in the disease process?
Momeni A, Sorice SC, Valenzuela A, et al.
Microsurgery 2015; (35(6)):441-6 doi:10.1002/micr.22379.
PMID: 25585522 - 19
Revision periarterial sympathectomy for recurrent digital ischaemia: a report with 11 patients.
Rudolph M, Butler K, Prabhu S, et al.
The Journal of hand surgery, European volume 2021; (46(8)):883-890 doi:10.1177/17531934211019572.
PMID: 34107782 - 20
Is Botulinum Toxin Useful in Systemic Sclerosis Related Peripheral Vasculopathy? A Literature Review.
Guerra MG, Fonseca DGD, Samões B, et al.
Reumatologia clinica 2021; (17(6)):357-363 doi:10.1016/j.reuma.2020.04.006.
PMID: 32591260 - 21
Efficacy and Safety of Botulinum Toxin in Adults with Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
Senet P, Maillard H, Diot E, et al.
Arthritis & rheumatology (Hoboken, N.J.) 2023; (75(3)):459-467 doi:10.1002/art.42342.
PMID: 36066501
This page explains warning signs and specialist treatments for severe Raynaud's for informational purposes only and does not constitute medical advice. Seek prompt medical care for a persistent ulcer, rest pain, a cold or pale digit, tissue changes, or signs of infection.